A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
A Multiple-Dose Study to Investigate the Bioequivalence of Orforglipron (LY3502970) Capsules and Orforglipron Tablets in Participants With Obesity or Overweight Who Are Otherwise Healthy.
Sponsor: Eli Lilly and Company
A PHASE1 clinical study on Healthy and Obese, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 9 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Jul 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
-
Apr 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Mar 2025 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
First recorded
Jun 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .